Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
247 studies found for:    sirolimus cancer | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
sirolimus cancer | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine;   Drug: Sirolimus;   Drug: Vorinostat
2 Recruiting Anakinra or Denosumab and Everolimus in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Everolimus;   Drug: Anakinra;   Drug: Denosumab
3 Recruiting Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Metformin
4 Recruiting A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Vandetanib;   Drug: Everolimus
5 Not yet recruiting Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant NY-ESO-1 Protein;   Drug: Sirolimus
6 Recruiting Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression
Conditions: Head and Neck Cancer;   Lung Cancer
Interventions: Drug: Ceritinib (LDK378);   Drug: Ceritinib (LDK378) 750 mg;   Drug: Everolimus
7 Recruiting Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Conditions: Renal Cancer;   Chromophobe Renal Cell Carcinoma;   Birt-Hogg-Dube Syndrome
Intervention: Drug: Everolimus
8 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
9 Recruiting A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
10 Recruiting Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Castration Levels of Testosterone;   Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   PSA Progression;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus
11 Not yet recruiting Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Goserelin;   Drug: Letrozole
12 Recruiting Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Conditions: Recurrent Bladder Carcinoma;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus;   Procedure: Therapeutic Conventional Surgery
13 Recruiting Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: everolimus and letrozole
14 Recruiting Everolimus for Cancer With TSC1 or TSC2 Mutation
Conditions: TSC1;   TSC2;   Tuberous Sclerosis Complex;   MTOR
Intervention: Drug: Everolimus
15 Recruiting Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
16 Recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
17 Recruiting A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
Condition: Pancreatic Neuroendocrine Tumour Metastatic
Intervention: Drug: Everolimus 10 mg daily
18 Recruiting A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus;   Drug: Vinorelbine;   Drug: Trastuzumab
19 Recruiting Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus;   Drug: carboplatin;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
20 Recruiting A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Condition: Relapsed / Recurrent Germ Cell Tumors
Interventions: Drug: Erlotinib;   Drug: Sirolimus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.